Artiva Biotherapeutics, Inc. (ARTV) AI Stock Analysis

• Market Cap: $87.69M
• Dividend Yield: N/A
• Average Volume (3M): 4.17M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.21
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 96
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.88
• Shares Outstanding: 24,425,762
• 10 Day Avg. Volume: 12,277,267
• 30 Day Avg. Volume: 4,166,063
• PEG Ratio: -0.01
• Price to Book (P/B): 1.32
• Price to Sales (P/S): 978.41
• P/FCF Ratio: -4.41
• Enterprise Value/Market Cap: -1.05
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 139.47
• Enterprise Value/Ebitda: 1.12
• 1Y Price Target: $16.50
• Price Target Upside: 389.61% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $4.00 ▲(18.69% Upside)

Artiva Biotherapeutics, Inc. shows potential with revenue growth and improved equity, but significant challenges remain in profitability and cash flow. Technical indicators suggest a mildly positive trend, but valuation metrics highlight the company's current unprofitability. The absence of earnings call and corporate events data limits further insights.

Positive Factors

Innovative Product Pipeline

The promising data from AlloNK trials indicates potential for groundbreaking therapies in autoimmune diseases, enhancing long-term growth prospects.

Regulatory Advancements

FDA Fast Track status for AlloNK could expedite development and approval processes, accelerating market entry and strengthening competitive position.

Revenue Growth

The revenue growth trajectory suggests increasing market acceptance and potential for scaling operations, supporting long-term business sustainability.

Negative Factors

Profitability Challenges

Persistent negative profit margins highlight ongoing operational inefficiencies, posing risks to financial stability and long-term viability.

Cash Flow Issues

Negative free cash flow indicates reliance on external financing, limiting financial flexibility and potentially hindering strategic investments.

High Debt Levels

Elevated debt levels can strain resources and limit growth opportunities, impacting long-term financial health and operational agility.

Artiva Biotherapeutics, Inc. Business Overview & Revenue Model

Company Description

Artiva Biotherapeutics, Inc. is a biopharmaceutical company focused on developing innovative cell therapies for the treatment of cancer. Utilizing its proprietary technology platforms, Artiva is dedicated to advancing the next generation of natural killer (NK) cell therapies, which harness the body's immune system to target and eliminate cancer cells. The company operates within the biotechnology sector, and its core products include engineered NK cell therapies designed to improve the effectiveness of cancer treatment while minimizing side effects.

How the Company Makes Money

Artiva Biotherapeutics generates revenue primarily through the development and commercialization of its cell therapy products. The company may secure funding through various channels, including equity financing, grants, and collaborations with larger pharmaceutical companies. Key revenue streams could include upfront payments, milestone payments, and royalties from partnerships and licensing agreements related to its NK cell therapy products. Additionally, Artiva could generate income through clinical trial collaborations and research agreements aimed at advancing its therapeutic candidates, as well as potential future sales of approved therapies once they enter the market.

Artiva Biotherapeutics, Inc. Financial Statement Overview

Summary

Artiva Biotherapeutics, Inc. is experiencing revenue growth and improvements in equity, yet continues to face profitability and cash flow challenges. The company demonstrates potential in its revenue trajectory, but operational inefficiencies and reliance on external financing pose significant risks.

Income Statement

Artiva Biotherapeutics, Inc. has demonstrated significant revenue growth from $2,002,000 in 2021 to $251,000 in 2024, indicating a positive trajectory. However, the company is still facing substantial net losses, with a net profit margin of -232.9% in 2024. The EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet shows improvement in stockholders' equity, moving from negative to positive in 2024, but the company still has a high debt-to-equity ratio due to previous negative equity. The equity ratio improved to 89.1% in 2024, showing enhanced financial stability despite previous challenges.

Cash Flow

Cash flow analysis indicates difficulties in generating positive free cash flow, with a free cash flow of -$55.7 million in 2024. The operating cash flow to net income ratio is negative, pointing to challenges in converting earnings to cash. There is a growth in financing cash flow, reflecting reliance on external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	251.00K	33.49M	4.93M	2.00M	0.00
Gross Profit	-662.00K	251.00K	33.49M	4.93M	2.00M	0.00
EBITDA	-82.23M	-64.85M	-28.41M	-58.67M	-71.58M	-17.52M
Net Income	-72.31M	-58.49M	-27.70M	-58.39M	-71.83M	-17.99M
Balance Sheet
Total Assets	148.86M	209.58M	105.11M	133.05M	169.93M	29.23M
Cash, Cash Equivalents and Short-Term Investments	122.97M	185.43M	76.97M	102.53M	160.92M	25.44M
Total Debt	11.69M	14.35M	16.91M	19.45M	1.74M	2.12M
Total Liabilities	19.64M	22.94M	267.13M	273.75M	258.78M	50.80M
Stockholders Equity	129.22M	186.64M	-162.01M	-140.70M	-88.86M	-21.57M
Cash Flow
Free Cash Flow	-78.91M	-55.67M	-50.69M	-57.13M	-17.03M	-13.82M
Operating Cash Flow	-76.67M	-55.03M	-47.43M	-50.83M	-15.30M	-13.54M
Investing Cash Flow	46.41M	-120.46M	-25.98M	-6.30M	-1.72M	-284.00K
Financing Cash Flow	100.00K	162.23M	24.39M	-1.26M	152.75M	37.40M

Artiva Biotherapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.37
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARTV, the sentiment is Negative. The current price of 3.37 is below the 20-day moving average (MA) of 3.59, below the 50-day MA of 3.48, and above the 200-day MA of 2.98, indicating a neutral trend. The MACD of -0.11 indicates Positive momentum. The RSI at 47.13 is Neutral, neither overbought nor oversold. The STOCH value of 21.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARTV.

Artiva Biotherapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPTX	53 Neutral	$76.47M	-0.69	-49.78%	―	-82.16%	14.58%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ARTV	44 Neutral	$87.69M	-1.16	-47.96%	―	―	―
ABVC	43 Neutral	$68.53M	-12.64	-40.32%	―	56.52%	75.22%
PLRX	37 Underperform	$98.83M	-0.47	-64.27%	―	―	14.19%
JSPR	35 Underperform	$47.01M	―	-191.12%	―	―	-24.38%
ACET	27 Underperform	$105.79M	-0.53	-71.73%	―	―	25.89%

Artiva Biotherapeutics, Inc. Corporate Events

Artiva Biotherapeutics Reports Increased Losses Amid Ongoing Development

Artiva Biotherapeutics, Inc. is a biopharmaceutical company focused on developing off-the-shelf, allogeneic NK cell-based therapies for autoimmune diseases and cancers, headquartered in San Diego, California. In its latest earnings report for the quarter ending September 30, 2025, Artiva Biotherapeutics reported a net loss of $21.5 million, reflecting an increase from the $17.5 million loss in the same period last year. The company has not yet generated revenue from product sales, as its therapies are still in the development phase. Key financial highlights include a decrease in cash and cash equivalents to $25.5 million from $40.2 million at the end of 2024, and a reduction in short-term investments from $145.2 million to $97.5 million. Operating expenses rose to $22.9 million, driven by increased research and development costs. Despite the financial losses, Artiva Biotherapeutics continues to focus on advancing its lead product candidate, AlloNK, through clinical development. Looking ahead, the company remains committed to its strategic goals of developing and commercializing its NK cell therapies, with management expressing confidence in securing additional funding to support ongoing operations.

Artiva Biotherapeutics Reports Positive AlloNK Trial Results

On November 12, 2025, Artiva Biotherapeutics announced positive initial safety and translational data from clinical trials of AlloNK in combination with rituximab or obinutuzumab for treating autoimmune diseases. The trials demonstrated that AlloNK was well tolerated, with no serious adverse events, and showed consistent B-cell depletion, comparable to CD19-auto-CAR-T therapies. This data supports the feasibility of administering AlloNK in outpatient and community settings, potentially addressing unmet needs in refractory rheumatoid arthritis, with plans for further clinical response data and FDA interactions in 2026.

The most recent analyst rating on (ARTV) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Artiva Biotherapeutics, Inc. stock, see the ARTV Stock Forecast page.

Artiva Biotherapeutics Advances with Promising NK Cell Therapy Study

Artiva Biotherapeutics, Inc. is conducting a Phase 2a clinical study titled ‘An Open-label Phase 2a Study to Evaluate the Safety and Efficacy of AlloNK®, an Allogeneic Cord Blood-derived NK Cell Therapy, in Combination With Rituximab in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.’ The study aims to assess the safety and efficacy of AlloNK®, a non-genetically modified NK cell therapy, combined with Rituximab for treating refractory rheumatoid arthritis, Sjögren’s disease, idiopathic inflammatory myopathies, and systemic sclerosis. This research is significant as it explores innovative treatments for challenging rheumatologic conditions.

Artiva Biotherapeutics Advances Lupus Treatment with Innovative NK-Cell Therapy

Artiva Biotherapeutics, Inc. is conducting a Phase 1 clinical trial titled A Phase 1 Study to Evaluate the Efficacy and Safety of AB-101, an Allogeneic Cord Blood-Derived NK-Cell Therapy in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus. The study aims to assess the safety, tolerability, and preliminary activity of AB-101, a natural killer cell therapy, in combination with B-cell depleting monoclonal antibodies in patients with relapsed or refractory lupus nephritis or systemic lupus erythematosus.

Artiva Biotherapeutics Advances in Cancer Therapy with GCC2005 Study Update

Study Overview: The clinical study titled A Phase 1, Multicenter Trial to Assess the Safety, Tolerability, and Preliminary Efficacy of GCC2005 With Lymphodepleting Chemotherapy in Treatment of Patients With Relapsed or Refractory NK and T-cell Malignancies aims to evaluate the safety, tolerability, and preliminary efficacy of GCC2005 in patients with relapsed or refractory NK and T-cell malignancies. This study is significant as it targets patients who have undergone at least two prior lines of therapy, offering a potential new treatment avenue.

Artiva Biotherapeutics Reports Progress in Clinical Trials

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing accessible cell therapies for autoimmune diseases and cancers, utilizing its lead program AlloNK® to enhance treatment efficacy.